NCM·Healthcare·$508M·#245 / 520 in Healthcare
OVID Ovid Therapeutics Inc.
46SPECULATIVE
CATEGORY BREAKDOWN
GROWTH100
QUALITY40
STABILITY35
VALUATION0
GOVERNANCE35
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+1181.3%
100
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
4 months
7
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
10.3%
92
< 25% strong
Price / Sales
Market cap relative to trailing revenue
70.0x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
596
100
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
7.5%
53
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+143.3%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE OVID WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when OVID's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.